<DOC>
	<DOCNO>NCT02944123</DOCNO>
	<brief_summary>East Asian patient require optimal dose new P2Y12 inhibitor ( prasugrel ticagrelor ) determine safer treatment well outcome . Whether low dose regimen adequate clinical practice Korea unclear . Therefore , investigator aim evaluate efficacy safety half dose new oral P2Y12 inhibitor Korean patient acute coronary syndrome ( ACS ) undergo percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Half Dose Prasugrel Ticagrelor Acute Coronary Syndrome ( HOPE-TAILOR )</brief_title>
	<detailed_description>In recent year , new oral P2Y12 receptor blocker ( prasugrel ticagrelor ) strong recommendation management patient ACS undergoing ( PCI ) . These drug provide profound inhibitory effect clopidogrel , could lead mark reduction ischemic event , relatively increase bleed complication , specific low body weight , especially woman East Asian patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients present acute coronary syndrome undergoing primary PCI . Patients receive DAPT ( conventional dose P2Y12 inhibitors+aspirin ) least 1 month . Patients provide write informed consent prior enrollment . Low body weight ( &lt; 55kg ) . History transient ischemic attack stroke . History upper gastrointestinal bleeding recent 6 month . Renal dysfunction define serum creatinine &gt; 2.5 mg/dl Severe hepatic dysfunction define serum transaminase &gt; 3 time normal limit On treatment oral anticoagulant ( Vitamin K antagonist , dabigatran , rivaroxaban ) . Bleeding tendency . Thrombocytopenia define platelet &lt; 100,000/ml . Anemia define hemoglobin &lt; 10 g/dl . Current treatment drug interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , telithromycin . Known severe chronic obstructive pulmonary disease bradycardia ( sick sinus syndrome ( SSS ) high degree AV block without pacemaker protection ) . Contraindication study drug .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Half dose</keyword>
	<keyword>Newer oral P2Y12 inhibitor</keyword>
	<keyword>Acute coronary syndrome</keyword>
</DOC>